×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder
Le patient oncologique en salle interventionnelle n’est plus une exception, il relève d’une prise en charge particulière.
Les consultations et l’imagerie jouent un rôle important dans la détection et la caractérisation des lésions afin de planifier la procédure interventionnelle.
Dans le cadre des cancers hépatiques, la chimio-embolisation est un des 3 principaux traitements avec la radio-embolisation et l’ablation percutanée.
Le but de ce live est d’échanger avec les experts sur les éléments qui amènent à la chimio-embolisation et sur les challenge de cette procédure.
Programme
|
12:30
|
Introduction et Présentation des objectifs
|
|
12:35
|
Le début du parcours patient : HOPE une consultation pluridisciplinaire
Discussion avec les experts
|
| 12:55 |
La RCP
Discussion avec les experts
|
|
13:05
|
Le staff : pour engager l’ensemble des équipes
Discussion avec les experts
|
|
13:10
|
Traitement de chimio-embolisation à l’aide de solution de guidage avancée
Discussion avec les experts
|
|
13:30
|
Conclusion et messages clés
|
Objectifs
- Rôles des différentes consultations qui amènent à la planification d’une chimio-embolisation dans le cadre du cancer hépatique – valorisation du parcours patient
- Cohésion entre les équipes médicales et paramédicales pour une meilleur prise en charge du patient
- Prise en charge des chimio-embolisations avec un plateau technique innovant
- Solution de guidage avancée en salle interventionnelle lors du traitement par chimio-embolisation
- Echanger avec les experts sur le devenir des patients qui ont bénéficié de cette prise en charge
Audience
- Radiologues interventionnels procédant à des chimio-embolisations
- Chirurgiens et cliniciens impliqués dans la prise en charge du patient oncologique
- Paramédicaux
Shooting date : 2019-02-05
Last update : 2020-10-16
Last update : 2020-10-16
Suggestions
Wednesday, March 30th 2022 from 06pm to 07:30pm (GMT+2)
Honolulu : Wednesday, March 30th 2022 from 07am to 08:30am (GMT+2)
San Francisco : Wednesday, March 30th 2022 from 10am to 11:30am (GMT+2)
New York : Wednesday, March 30th 2022 from 01pm to 02:30pm (GMT+2)
Buenos Aires : Wednesday, March 30th 2022 from 02pm to 03:30pm (GMT+2)
Reykjavik : Wednesday, March 30th 2022 from 05pm to 06:30pm (GMT+2)
London / Dublin : Wednesday, March 30th 2022 from 06pm to 07:30pm (GMT+2)
Paris / Berlin : Wednesday, March 30th 2022 from 07pm to 08:30pm (GMT+2)
Istanbul : Wednesday, March 30th 2022 from 08pm to 09:30pm (GMT+2)
Moscou / Dubaï : Wednesday, March 30th 2022 from 09pm to 10:30pm (GMT+2)
Bangkok : Thursday, March 31st 2022 from 12am to 01:30am (GMT+2)
Shanghai : Thursday, March 31st 2022 from 01am to 02:30am (GMT+2)
Tokyo : Thursday, March 31st 2022 from 02am to 03:30am (GMT+2)
Sydney : Thursday, March 31st 2022 from 04am to 05:30am (GMT+2)
Wellington : Thursday, March 31st 2022 from 06am to 07:30am (GMT+2)
San Francisco : Wednesday, March 30th 2022 from 10am to 11:30am (GMT+2)
New York : Wednesday, March 30th 2022 from 01pm to 02:30pm (GMT+2)
Buenos Aires : Wednesday, March 30th 2022 from 02pm to 03:30pm (GMT+2)
Reykjavik : Wednesday, March 30th 2022 from 05pm to 06:30pm (GMT+2)
London / Dublin : Wednesday, March 30th 2022 from 06pm to 07:30pm (GMT+2)
Paris / Berlin : Wednesday, March 30th 2022 from 07pm to 08:30pm (GMT+2)
Istanbul : Wednesday, March 30th 2022 from 08pm to 09:30pm (GMT+2)
Moscou / Dubaï : Wednesday, March 30th 2022 from 09pm to 10:30pm (GMT+2)
Bangkok : Thursday, March 31st 2022 from 12am to 01:30am (GMT+2)
Shanghai : Thursday, March 31st 2022 from 01am to 02:30am (GMT+2)
Tokyo : Thursday, March 31st 2022 from 02am to 03:30am (GMT+2)
Sydney : Thursday, March 31st 2022 from 04am to 05:30am (GMT+2)
Wellington : Thursday, March 31st 2022 from 06am to 07:30am (GMT+2)
Cholangiocarcinome intrahépatique
Actualités dans la prise en charge transversale des cancers des voies biliaires
Share
Monday, September 12th 2022 from 06pm to 07:30pm (GMT+2)
Honolulu : Monday, September 12th 2022 from 07am to 08:30am (GMT+2)
San Francisco : Monday, September 12th 2022 from 10am to 11:30am (GMT+2)
New York : Monday, September 12th 2022 from 01pm to 02:30pm (GMT+2)
Buenos Aires : Monday, September 12th 2022 from 02pm to 03:30pm (GMT+2)
Reykjavik : Monday, September 12th 2022 from 05pm to 06:30pm (GMT+2)
London / Dublin : Monday, September 12th 2022 from 06pm to 07:30pm (GMT+2)
Paris / Berlin : Monday, September 12th 2022 from 07pm to 08:30pm (GMT+2)
Istanbul : Monday, September 12th 2022 from 08pm to 09:30pm (GMT+2)
Moscou / Dubaï : Monday, September 12th 2022 from 09pm to 10:30pm (GMT+2)
Bangkok : Tuesday, September 13th 2022 from 12am to 01:30am (GMT+2)
Shanghai : Tuesday, September 13th 2022 from 01am to 02:30am (GMT+2)
Tokyo : Tuesday, September 13th 2022 from 02am to 03:30am (GMT+2)
Sydney : Tuesday, September 13th 2022 from 04am to 05:30am (GMT+2)
Wellington : Tuesday, September 13th 2022 from 06am to 07:30am (GMT+2)
San Francisco : Monday, September 12th 2022 from 10am to 11:30am (GMT+2)
New York : Monday, September 12th 2022 from 01pm to 02:30pm (GMT+2)
Buenos Aires : Monday, September 12th 2022 from 02pm to 03:30pm (GMT+2)
Reykjavik : Monday, September 12th 2022 from 05pm to 06:30pm (GMT+2)
London / Dublin : Monday, September 12th 2022 from 06pm to 07:30pm (GMT+2)
Paris / Berlin : Monday, September 12th 2022 from 07pm to 08:30pm (GMT+2)
Istanbul : Monday, September 12th 2022 from 08pm to 09:30pm (GMT+2)
Moscou / Dubaï : Monday, September 12th 2022 from 09pm to 10:30pm (GMT+2)
Bangkok : Tuesday, September 13th 2022 from 12am to 01:30am (GMT+2)
Shanghai : Tuesday, September 13th 2022 from 01am to 02:30am (GMT+2)
Tokyo : Tuesday, September 13th 2022 from 02am to 03:30am (GMT+2)
Sydney : Tuesday, September 13th 2022 from 04am to 05:30am (GMT+2)
Wellington : Tuesday, September 13th 2022 from 06am to 07:30am (GMT+2)
SIRT in 2022 – What have we learned and where are we heading to
Share
